Zealand Pharma

Peptide therapeutics

ZEAL · Nasdaq Copenhagen · Denmark

Public Market Listing

ZEALNasdaq Copenhagen

Nasdaq Copenhagen primary exchange listing

Live quotes, historical charts, and market capitalization for Zealand Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(6 total)
6Total Assets
2Approved
2Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 6 of 6 assets
Target & Modality
dasiglucagon(Zegalogue)
Approved
Glucagon receptor (agonist)Peptide
Diabetes / Hypoglycemia
Severe Hypoglycemia
lixisenatide(Adlyxin / Lyxumia)
Approved
GLP-1 receptorPeptide
Type 2 Diabetes
Phase 3
Amylin receptor · Amylin/calcitonin receptor (dual)Peptide
Obesity
Phase 3
GLP-1/glucagon receptor (dual)Peptide
ObesityType 2 DiabetesMASH / NASH
Phase 2
GLP-1/GLP-2 receptor (dual)Peptide
Obesity
Phase 1
GIP receptorPeptide
Obesity

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
petrelintidePhase 2Obesity or Overweight
Est. primary completion 2027-11-12 · NCT07589686 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
survodutidePhase 3Type 2 Diabetes
Est. primary completion 2028-01-17 · NCT07754461 · CT.gov ↗
What to watch
July 2028 (1)
survodutidePhase 3Obesity
Est. primary completion 2028-07-26 · NCT07850050 · CT.gov ↗
What to watch
October 2028 (1)
petrelintidePhase 3Obesity or Overweight, Type 2 Diabetes
Est. primary completion 2028-10-20 · NCT07843485 · CT.gov ↗
What to watch
December 2028 (1)
petrelintidePhase 3Obesity or Overweight
Est. primary completion 2028-12-21 · NCT07843498 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
survodutidePhase 3Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Est. primary completion 2029-04-29 · NCT07850063 · CT.gov ↗
What to watch
June 2029 (1)
survodutidePhase 3Metabolic Dysfunction Associated Steatohepatitis
Est. primary completion 2029-06-05 · NCT06632457 · CT.gov ↗
What to watch
November 2029 (1)
survodutidePhase 3Obesity
Est. primary completion 2029-11-06 · NCT07855900 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
petrelintidePhase 3Obesity or Overweight, Cardiovascular Disease
Est. primary completion 2030-07-28 · NCT07843472 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
survodutidePhase 3Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Est. primary completion 2031-12-27 · NCT06632444 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 October 2026Topline resultpetrelintideZUPREME-2 Phase 2 trial met its primary endpoint
Zealand Pharma A/S · Source ↗
1 October 2026Topline resultsurvodutideSYNCHRONIZE-2 Phase III met co-primary endpoints
Boehringer Ingelheim · Source ↗
29 April 2026Topline resultsurvodutideSYNCHRONIZE-1 Phase III met co-primary endpoints
Boehringer Ingelheim · Source ↗
5 March 2026Topline resultpetrelintideZUPREME-1: petrelintide met primary endpoint in Phase 2 obesity trial
Zealand Pharma · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$5.3M—$2.2B—report ↗
View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$1.3B—$2.6B—report ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.4B—$2.4B—report ↗

For FY 2025, Zealand Pharma reported revenue of $1,393.89M, up 15,234.3% YoY, with R&D spend not disclosed and cash and equivalents of $2,378.16M. Net income/loss and quarterly net burn were not disclosed, though the company reported an operating result of DKK 6,959M.

The company guided 2026 net operating expenses (excl. OOI) to DKK 2,700–3,300M and noted eligibility for potential Roche milestones of USD 700M, including USD 575M tied to Phase 3a initiation and USD 125M in Q2 2026. Key events included the Roche collaboration for petrelintide, expected Phase 2 ZUPREME-1 topline data in Q1 2026, Phase 3 survodutide data expected during 2026, dasiglucagon NDA resubmission planned for H2 2026, glepaglutide Phase 3 EASE-5 recruitment and EU MAA submission, positive Phase 1a SAD data for ZP9830, and plans for a Boston research site and a first-in-human trial for ZP6590 in 2026.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-9M$1.4B$168M$2.5B—report ↗
2024-FY$9.1M—$1.3B—report ↗